246 related articles for article (PubMed ID: 20424599)
21. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
[TBL] [Abstract][Full Text] [Related]
22. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
[TBL] [Abstract][Full Text] [Related]
24. Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction.
Chai Z; Zhang X; Dobbins AL; Samulski RJ; Merricks EP; Nichols TC; Li C
Hum Gene Ther; 2022 Feb; 33(3-4):119-130. PubMed ID: 34617445
[TBL] [Abstract][Full Text] [Related]
25. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
[TBL] [Abstract][Full Text] [Related]
26. Adeno-associated virus-mediated gene transfer for hemophilia B.
High KA
Int J Hematol; 2002 Nov; 76(4):310-8. PubMed ID: 12463593
[TBL] [Abstract][Full Text] [Related]
27. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.
Arruda VR; Fields PA; Milner R; Wainwright L; De Miguel MP; Donovan PJ; Herzog RW; Nichols TC; Biegel JA; Razavi M; Dake M; Huff D; Flake AW; Couto L; Kay MA; High KA
Mol Ther; 2001 Dec; 4(6):586-92. PubMed ID: 11735343
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
Larson PJ; High KA
Adv Exp Med Biol; 2001; 489():45-57. PubMed ID: 11554590
[No Abstract] [Full Text] [Related]
30. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
31. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.
Chao H; Liu Y; Rabinowitz J; Li C; Samulski RJ; Walsh CE
Mol Ther; 2000 Dec; 2(6):619-23. PubMed ID: 11124063
[TBL] [Abstract][Full Text] [Related]
32. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
Xu L; Gao C; Sands MS; Cai SR; Nichols TC; Bellinger DA; Raymer RA; McCorquodale S; Ponder KP
Blood; 2003 May; 101(10):3924-32. PubMed ID: 12531787
[TBL] [Abstract][Full Text] [Related]
33. New and improved AAVenues: current status of hemophilia B gene therapy.
Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
[TBL] [Abstract][Full Text] [Related]
35. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
36. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
Wiwanitkit V
Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
[TBL] [Abstract][Full Text] [Related]
37. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
[TBL] [Abstract][Full Text] [Related]
38. Portal vein delivery of viral vectors for gene therapy for hemophilia.
Sherman A; Schlachterman A; Cooper M; Merricks EP; Raymer RA; Bellinger DA; Herzog RW; Nichols TC
Methods Mol Biol; 2014; 1114():413-26. PubMed ID: 24557919
[TBL] [Abstract][Full Text] [Related]
39. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
[TBL] [Abstract][Full Text] [Related]
40. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
Jiang H; Pierce GF; Ozelo MC; de Paula EV; Vargas JA; Smith P; Sommer J; Luk A; Manno CS; High KA; Arruda VR
Mol Ther; 2006 Sep; 14(3):452-5. PubMed ID: 16822719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
